Human Papillomavirus and Cervical Intraepithelial Neoplasia

Persistent infection with high-risk human papillomavirus (HPV) is the necessary cause of cervical intraepithelial neoplasia (CIN) and invasive cervical cancer. CIN describes graded precancerous change in the cervical squamous epithelium, and its recognition in cytology and histology — together with detection of the causal virus — forms the biological foundation of cervical cytopathology and screening.

Definition

Cervical intraepithelial neoplasia is a spectrum of HPV-associated dysplastic change confined to the cervical squamous epithelium, graded by the proportion of epithelium involved (CIN 1-3) or as low- and high-grade squamous intraepithelial lesions, representing a precursor to invasive squamous cell carcinoma.

Scope

This topic covers the natural history from HPV infection through productive and transforming infection to CIN grades and invasion, the viral oncoproteins involved, the morphologic correlates seen in cytology and histology, and the rationale for HPV testing and vaccination. It is a reference description of the disease entity and its mechanism, not individual clinical guidance.

Core questions

• How does persistent high-risk HPV infection drive progression from infection to CIN to invasive cancer?
• Which viral oncoproteins disrupt cell-cycle control and how does this appear morphologically?
• How do CIN grades and the low-/high-grade SIL terminology relate to cancer risk?
• How do HPV testing and prophylactic vaccination alter the natural history and burden of disease?

Key concepts

• High-risk HPV types (e.g. HPV-16 and HPV-18)
• Persistent versus transient infection
• E6 and E7 viral oncoproteins
• Productive versus transforming infection
• CIN grading (CIN 1-3) and LSIL/HSIL
• p16 immunohistochemistry as a surrogate marker
• Prophylactic HPV vaccination

Mechanisms

High-risk HPV infects basal keratinocytes of the transformation zone. In transforming infection the viral oncoproteins E6 and E7 inactivate the tumour-suppressor proteins p53 and retinoblastoma (pRb), respectively, deregulating the cell cycle and driving genomic instability. This produces the disordered maturation, nuclear atypia, and increased mitotic activity that define CIN and that exfoliate as abnormal cells detectable on cytology; overexpression of p16 serves as a histologic surrogate for transforming HPV activity (zurhausen-2002, schiffman-2007).

Clinical relevance

Because high-risk HPV is necessary for cervical cancer, detecting the virus and its precursor lesions allows the disease to be intercepted before invasion, and prophylactic vaccination reduces incidence of both CIN and invasive cancer. This entry describes the entity and its mechanism for reference; it does not provide individualised screening, diagnostic, or treatment recommendations.

Epidemiology

High-risk HPV DNA is detected in essentially all invasive cervical cancers worldwide, establishing the virus as a necessary cause (walboomers-1999). Most infections are transient and clear spontaneously; only a minority persist and progress, but cervical cancer remains a major global cause of cancer death. Population studies of HPV vaccination show substantial reductions in invasive cervical cancer among vaccinated cohorts (lei-2020).

History

Harald zur Hausen's hypothesis and subsequent identification of HPV-16 and HPV-18 in cervical cancer, for which he shared the 2008 Nobel Prize, reframed cervical neoplasia as an infectious disease. Large epidemiologic studies then established HPV as a necessary cause, leading to HPV-based screening and, from 2006, prophylactic vaccines that target the principal oncogenic types (zurhausen-2002, walboomers-1999).

Debates

How best to predict which CIN lesions will progress

Many low-grade lesions regress while a minority progress, and identifying biomarkers (such as p16/Ki-67 or HPV genotype and viral persistence) that distinguish progressive from regressive disease remains an active area, with implications for avoiding overtreatment.

Key figures

• Harald zur Hausen
• Nubia Muñoz
• F. Xavier Bosch
• Mark Schiffman
• Jan Walboomers

Seminal works

• zurhausen-2002
• walboomers-1999
• schiffman-2007

Frequently asked questions

Does having high-risk HPV mean a person will get cervical cancer?

No. Most HPV infections clear on their own without causing disease. Only a small fraction of infections persist and, over years, can drive precancerous change; this is why screening focuses on detecting persistent infection and precursor lesions rather than transient infection.

What is the relationship between CIN grades and the Bethesda LSIL/HSIL terms?

CIN 1 broadly corresponds to LSIL (low-grade, often transient HPV effect), while CIN 2-3 correspond to HSIL (high-grade, transforming infection with higher progression risk). The two-tiered cytologic terminology was adopted to reflect this biological distinction.